Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE + Lenvatinib + HAIC in uHCC
NCT06364007Phase 2Recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab, durvalumab, lenvatinib in hepatocellular carcinoma (HCC). Started Mar 2024; status: recruiting.
02
Drugs
tremelimumabdurvalumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06364007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364007.